271 related articles for article (PubMed ID: 15911102)
1. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma.
Cheng PN; Leung YC; Lo WH; Tsui SM; Lam KC
Cancer Lett; 2005 Jun; 224(1):67-80. PubMed ID: 15911102
[TBL] [Abstract][Full Text] [Related]
2. Arginase release by primary hepatocytes and liver slices results in rapid conversion of arginine to urea in cell culture media.
Peters SJ; Haagsman HP; van Norren K
Toxicol In Vitro; 2008 Jun; 22(4):1094-8. PubMed ID: 18348903
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
[TBL] [Abstract][Full Text] [Related]
5. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
6. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
[TBL] [Abstract][Full Text] [Related]
7. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma arginase-1 does not affect plasma arginine in patients undergoing liver resection.
van de Poll MC; Hanssen SJ; Berbée M; Deutz NE; Monbaliu D; Buurman WA; Dejong CH
Clin Sci (Lond); 2008 Feb; 114(3):231-41. PubMed ID: 17708746
[TBL] [Abstract][Full Text] [Related]
10. [A comparative study of tumor responses of hepatocellular carcinoma and colorectal hepatic metastasis to cytotoxic anticancer drug].
Ku Y; Shiki H; Iwasaki T; Tominaga M; Maekawa Y; Samizo M; Fukumoto T; Kanamaru T; Nakamura T; Yamamoto M
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1355-61. PubMed ID: 8394062
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant hepatic chemotherapy after resection of solitary hepatocellular carcinoma associated with hepatitis B virus cirrhosis.
Wen J; Shen WL; Yang SH
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):224-7. PubMed ID: 16698580
[TBL] [Abstract][Full Text] [Related]
12. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
[TBL] [Abstract][Full Text] [Related]
14. Arginine deiminase, a potential anti-tumor drug.
Ni Y; Schwaneberg U; Sun ZH
Cancer Lett; 2008 Mar; 261(1):1-11. PubMed ID: 18179862
[TBL] [Abstract][Full Text] [Related]
15. Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
Lin ZY; Chuang WL; Chuang YH; Yu ML; Hsieh MY; Wang LY; Tsai JF
J Gastroenterol Hepatol; 2006 Feb; 21(2):398-405. PubMed ID: 16509865
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
Ikeda M; Okusaka T; Ueno H; Morizane C; Kojima Y; Iwasa S; Hagihara A
Jpn J Clin Oncol; 2008 Oct; 38(10):675-82. PubMed ID: 18716041
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
19. [Growth rate of hepatocellular carcinoma and nutritional state].
Akamatsu K; Tada K; Ito Y; Ohkubo K
Gan To Kagaku Ryoho; 1992 May; 19(5):607-11. PubMed ID: 1316099
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
